Quick Answer
Regenerative Medical Technology Group Inc. reported Stockholders Equity of -$27.36 million for the year ending 2024.
- Regenerative Medical Technology Group Inc. showed a decrease of -25.5% in Stockholders Equity from 2023 to 2024.
- This data is from Regenerative Medical Technology Group Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2016 to 2024 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: -$2.56 million | Q2 2018: -$4.28 million | Q3 2018: -$3.25 million | Q1 2019: -$7.22 million | Q2 2019: -$4.28 million | Q3 2019: -$5.98 million | Q4 2019: -$7.36 million | Q1 2020: -$8.19 million | Q2 2020: -$11.54 million | Q3 2020: -$18.93 million | Q1 2021: -$6.50 million | Q2 2021: -$1.86 million | Q3 2021: -$5.51 million | Q1 2022: -$8.17 million | Q2 2022: -$11.00 million | Q3 2022: -$11.00 million | Q1 2023: -$13.65 million | Q2 2023: -$15.68 million | Q3 2023: -$21.54 million | Q4 2023: -$21.80 million | Q1 2024: -$23.76 million | Q2 2024: -$25.83 million | Q3 2024: -$26.72 million | Q4 2024: -$27.36 million | Q1 2025: -$28.12 million | Q2 2025: -$29.02 million | Q3 2025: -$30.05 million.
- Over the full 9 years of available data (2016 to 2024), Regenerative Medical Technology Group Inc.'s Stockholders Equity has declined by 396.7%.
- Historical annual values: Fiscal year 2024: -$27.36 million | Fiscal year 2023: -$21.80 million | Fiscal year 2022: -$11.98 million | Fiscal year 2021: -$6.76 million | Fiscal year 2020: -$6.41 million | Fiscal year 2019: -$7.36 million | Fiscal year 2018: -$4.54 million | Fiscal year 2017: -$2.56 million | Fiscal year 2016: -$5.51 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: